# GEOMETRY mono-1

Source: https://onco.cc/trials/geometry-mono-1/  
OnCo record `geometry-mono-1` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GEOMETRY mono-1 showed that capmatinib shrinks two thirds of untreated lung cancers with a MET exon 14 skipping mutation and about four in ten after chemotherapy, which made MET exon 14 the seventh lung cancer driver with an approved targeted drug.

## Summary

GEOMETRY mono-1 enrolled patients with advanced non-small-cell lung cancer into cohorts defined by MET exon 14 skipping or by the degree of MET amplification and by prior treatment, all receiving capmatinib 400 mg twice daily. MET exon 14 skipping, found in 3 to 4 percent of lung cancers and often in older patients and sarcomatoid tumours, had responded poorly to the multikinase inhibitor crizotinib.

Among the exon 14 cohorts the response rate was 68 percent in 28 treatment-naive patients and 41 percent in 69 previously treated patients, with median durations of response of 12.6 and 9.7 months and activity against brain metastases. Tumours with high MET amplification (gene copy number 10 or more) responded in about a third of cases; lower levels of amplification did not respond. Peripheral oedema and nausea were the main side effects.

The FDA granted accelerated approval in May 2020 and regular approval in 2022; tepotinib (VISION) followed with similar results, and the two drugs are interchangeable options.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-17
- Registry id: NCT02414139
- Phase: 2
- Setting: Advanced non-small-cell lung cancer with MET exon 14 skipping or MET amplification: capmatinib monotherapy in cohorts by prior treatment and MET gene copy number
- Sponsor: Novartis
- Result: Response rate 68% (treatment-naive, n=28) and 41% (previously treated, n=69) in MET exon 14 skipping disease; about a third in high-level MET amplification.
- Outcomes: Objective response rate, MET exon 14 skipping: Treatment-naive 68% vs Previously treated 41%
- Replication: VISION (tepotinib) reported a 46 percent response rate in the same population and both drugs are approved.

## Sources

- ClinicalTrials.gov NCT02414139: https://clinicaltrials.gov/study/NCT02414139
- New England Journal of Medicine 2020: https://doi.org/10.1056/NEJMoa2002787

## Connected records

- cancers: [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [MET](https://onco.cc/targets/met/)
- drugs: [Capmatinib](https://onco.cc/drugs/capmatinib/), [Crizotinib](https://onco.cc/drugs/crizotinib/)
- companies: [Novartis](https://onco.cc/companies/novartis/)
- terms: [MET amplification (bypass resistance)](https://onco.cc/terms/met-amplification/)

---
JSON: https://onco.cc/api/v1/entities/geometry-mono-1.json